Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2006 Oct 16;149(7):966. doi: 10.1038/sj.bjp.0706958

Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

K E Baker, L M Wood, M Whittaker, M J Curtis
PMCID: PMC2014698

Correction to: British Journal of Pharmacology (2006) 149, 269–276. doi:10.1038/sj.bjp.0706846

Due to a typesetting error, the QT interval was incorrectly defined as the ‘quantitative transmission (QT) interval' in the Abbreviation section and in column 2 on page 269. The correct definition should remain as QT interval.

The typesetters would like to apologise for this error.


Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES